This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...
A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...
A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...
Systematic review of 2L+ ADC strategies in triple-negative breast cancer (TNBC). First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer ...
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company,' 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RASand BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback